Form 4: Eli Lilly Director Defers Compensation into Stock

Eli Lilly & Co. Director J. Erik Fyrwald acquired 12.259 shares of common stock, deferring cash compensation into stock units under the Lilly Directors' Deferral Plan.

Summary

• J. Erik Fyrwald, a Director at Eli Lilly & Co. (LLY), acquired 12.259 shares of common stock.
• The transaction occurred on October 20, 2025, at a price of $808.96 per share.
• These shares were acquired as stock units under the Lilly Directors' Deferral Plan, in lieu of cash compensation.
• The stock units will be settled in shares of common stock following Mr. Fyrwald's separation from service.
• Following this transaction, Mr. Fyrwald beneficially owns a total of 74,763.656 shares of Eli Lilly & Co. common stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a director is increasing their beneficial ownership, aligning their interests with shareholders, even if it's through a compensation deferral rather than an open market purchase.

Positives

• Director J. Erik Fyrwald increased his beneficial ownership in Eli Lilly & Co. by acquiring 12.259 shares, signaling continued confidence in the company's future.
• The deferral of cash compensation into stock units aligns the director's financial interests more closely with those of long-term shareholders.

Future Outlook

The acquired stock units will be settled in shares of common stock following the reporting person's separation from service.

Management Comments

• J. Erik Fyrwald's decision to defer cash compensation into Eli Lilly & Co. stock units demonstrates a commitment to the company's long-term performance and shareholder value.

Industry Context

This transaction represents a routine insider compensation deferral, a common practice in publicly traded companies to align executive and director interests with shareholders. It does not directly reflect broader industry trends but is a standard mechanism for executive remuneration.

Comparison to Industry Standards

• Deferring cash compensation into equity is a common practice for directors across various industries, including pharmaceuticals, to foster alignment with shareholder interests.
• The use of a Rule 10b5-1 plan for such transactions is standard practice to ensure compliance with insider trading regulations and provide an affirmative defense.

Corporate Governance

Related Party Transactions

• The acquisition of shares by Director J. Erik Fyrwald through the Lilly Directors' Deferral Plan constitutes a related party transaction, as it involves compensation from the company to a director.

Stakeholder Impact

• Shareholders: Increased beneficial ownership by a director can be viewed positively, signaling confidence in the company's future and aligning management interests with shareholder returns.
• Employees: No direct impact mentioned.

Next Steps

• The stock units will be settled in shares of common stock following J. Erik Fyrwald's separation from service.

Key Dates

Keywords

Eli Lilly, LLY, Insider Transaction, Director Compensation, Stock Acquisition, Deferred Compensation, Form 4, Rule 10b5-1